# Olema Oncology Completes Enrollment in Pivotal Phase 3 OPERA-01 Breast Cancer Trial

> clinical trial · REPORTED · 2026-08-10

Olema Oncology announced on August 10, 2026 that it has completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027. The company also announced a clinical trial collaboration with Bayer to evaluate darolutamide in combination with OP-3136 in metastatic castration-resistant prostate cancer.

About Olema Oncology: Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and other solid tumor indications.

- Company: Olema Oncology
- Sector: oncology
- Primary source: https://www.sec.gov/Archives/edgar/data/0001750284/000119312526342334/olma-ex99_1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.